RTP-026, A POTENTIAL FIRST-IN-CLASS CARDIOPROTECTANT, SHOWS STRONG SAFETY AND PROMISING EFFICACY SIGNALS IN A PHASE 2a STUDY IN PATIENTS WITH SEVERE HEART ATTACK
ResoTher Pharma announces encouraging top-line results from its Phase 2a clinical study [...]
ResoTher Pharma initiates dosing in its Phase 2a clinical trial in myocardial infarction patients
ResoTher Pharma is pleased to announce that the first patient has been [...]
RTP-026, A POTENTIAL FIRST-IN-CLASS CARDIOPROTECTANT, SHOWS STRONG SAFETY AND PROMISING EFFICACY SIGNALS IN A PHASE 2a STUDY IN PATIENTS WITH SEVERE HEART ATTACK
ResoTher Pharma announces encouraging top-line results from its Phase 2a [...]
ResoTher Pharma initiates dosing in its Phase 2a clinical trial in myocardial infarction patients
ResoTher Pharma is pleased to announce that the first patient [...]
